Hennion & Walsh Asset Management Inc. Acquires 233,633 Shares of Kura Oncology, Inc. $KURA

Hennion & Walsh Asset Management Inc. raised its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 69.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 568,845 shares of the company’s stock after buying an additional 233,633 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Kura Oncology were worth $6,240,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Suvretta Capital Management LLC raised its holdings in shares of Kura Oncology by 5.7% in the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock valued at $89,099,000 after acquiring an additional 459,422 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Kura Oncology by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after purchasing an additional 39,105 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Kura Oncology by 5.7% during the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after purchasing an additional 264,000 shares in the last quarter. State Street Corp increased its position in shares of Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after purchasing an additional 1,587,959 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Kura Oncology by 36.6% in the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after purchasing an additional 820,020 shares during the last quarter.

Kura Oncology Price Performance

Shares of KURA opened at $9.57 on Monday. The firm has a market cap of $849.53 million, a P/E ratio of -2.86 and a beta of 0.38. The stock has a 50 day simple moving average of $10.09 and a two-hundred day simple moving average of $9.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. Kura Oncology, Inc. has a 1 year low of $5.45 and a 1 year high of $12.49.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The business had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, analysts forecast that Kura Oncology, Inc. will post -3.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on KURA shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a report on Monday, June 15th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research note on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.46.

Insider Activity

In related news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.60% of the company’s stock.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.